Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987395 | 0.90 | GLS (0.81) | GLSALDH1A1POLBATML3MBTL1 | |
| SCHEMBL14987396 | 0.89 | GLS (0.79) | GLSALDH1A1POLBATML3MBTL1 | |
| SCHEMBL21443428 | 0.84 | GLS (0.71) | GLSALDH1A1POLB | |
| SCHEMBL19003804 | 0.80 | GLS (0.65) | GLSALDH1A1POLB | |
| SCHEMBL19003803 | 0.79 | GLS (0.63) | GLSALDH1A1POLBGAA | |
| SCHEMBL10950901 | 0.79 | — | — | |
| SCHEMBL14977428 | 0.78 | ALDH1A1 (0.86) | GLSALDH1A1POLBATML3MBTL1 | |
| SCHEMBL14975757 | 0.78 | ALDH1A1 (0.95) | GLSALDH1A1POLBATML3MBTL1 | |
| SCHEMBL14987653 | 0.78 | GLS (0.83) | GLS | |
| SCHEMBL15742414 | 0.78 | GLS (0.63) | GLSALDH1A1POLBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191732-B2 | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | HANGZHOU JENNIFER BIOTECH CO LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200246274-A1 | GLUTAMINASE INHIBITOR DISCOVERY AND NANOPARTICLE-ENHANCED DELIVERY FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-08-06 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-10660861-B2 | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3620162-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | Calithera Biosciences Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-104220070-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2020-01-21 | — | — | CN | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8604016-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-6451828-B1 | USEFUL FOR NEUROPROTECTION AND IN TREATMENT OF HEPATIC ENCEPHALOPATHY; BIS(2-((5-CARBONYLAMINO)-1,3,4-THIADIAZOL-2-YL)ETHYL) ETHER OR SULFIDE DERIVATIVES | ELAN PHARMACEUTICALS, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020115698-A1 | SELECTIVE INHIBITION OF GLUTAMINASE BY BIS-THIADIAZOLES | ELAN PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885POLB 2684/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885POLB 2684/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885POLB 2684/4885 |
| US-20020115698-A1 | SELECTIVE INHIBITION OF GLUTAMINASE BY BIS-THIADIAZOLES | GLS2, GLS, GLUL | GLS 2/4885ALDH1A1 185/4885POLB 2355/4885 |
| US-20200246274-A1 | GLUTAMINASE INHIBITOR DISCOVERY AND NANOPARTICLE-ENHANCED DELIVERY FOR CANCER THERAPY | GLS2, GLS, GLUL | GLS 2/4885ALDH1A1 678/4885POLB 2694/4885 |
| US-10660861-B2 | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy | GLS2, GLS, GLUL | GLS 2/4885ALDH1A1 678/4885POLB 2694/4885 |
| US-11191732-B2 | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy | GLS2, GLS, GLUL | GLS 2/4885ALDH1A1 678/4885POLB 2694/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885POLB 2684/4885 |
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | GPX4, GPX1, SELENOI | GLS 54/4885ALDH1A1 1109/4885POLB 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.